The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.

Interstitial Lung Disease (ILD): In the PHAROS trial, 1 patient (1%) receiving MEKTOVI with BRAFTOVI developed pneumonitis. Assess new or progressive unexplained pulmonary symptoms or findings for ...

The Phase III study was held in Chinese locations and the HER2-targeting ADC Aidixi is unlikely to launch in markets outside ...

In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis ...

A new study suggests that these vaccines might boost the effects of immunotherapy drugs, perhaps by alerting the immune ...

Astellas Pharma (ALPMY) and Pfizer (PFE) announced positive results from the Phase 3 EV-303 clinical trial for PADCEV, a Nectin-4 directed ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. today announced positive results from the pivotal Phase 3 EV-303 clinical trial (also known as ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...

“DESTINY-Breast11 results support T-DXd [plus] THP as a more effective and less toxic neoadjuvant treatment compared with ddAC-THP, and it may become the preferred regimen for patients with high-risk, ...

Corcept Therapeutics Incorporated , a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by ...

In early April, the S&P 500 entered bear market territory, defined by a 20% decline from its recent peak. The index fell to 4 ...

In a market environment where low interest rates have become the norm, income-focused investors are increasingly turning to ...